"A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer.” RXPONDER

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515368-29-00

Acronym

GEICAM/2011-03_S1007

Enrollment

792

Registered

2024-10-10

Start date

2012-09-20

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with node positive breast cancer who do not have high Recurrence Scores (RS) by Oncotype DX®

Brief summary

Invasive Recurrence

Detailed description

Invasive Disease-Free Survival, Distant Disease-Free Survival, Local Disease-Free Interval., Overall Survival

Interventions

DRUGFLUOROURACIL

DRUGDOCETAXEL

DRUGEXEMESTANE

DRUGDOXORUBICIN

DRUGCYCLOPHOSPHAMIDE

DRUGEPIRUBICIN

DRUGLETROZOLE

DRUGTAMOXIFEN

DRUGANASTROZOLE

DRUGPACLITAXEL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Invasive Recurrence	—

Secondary

Measure	Time frame
Invasive Disease-Free Survival, Distant Disease-Free Survival, Local Disease-Free Interval., Overall Survival	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026